Knoll / Kelemen Advances in Pharmacological Research and Practice

Proceedings of the 4th Congress of the Hungarian Pharmacological Society, Budapest, 1985
1. Auflage 2013
ISBN: 978-1-4831-4801-4
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 432 Seiten, Web PDF

Advances in Pharmacological Research and Practice, Volume 1: Pharmacological Protection of the Myocardium presents the proceedings of the 4th Congress of the Hungarian Pharmacological Society, held in Budapest, Hungary in 1985. This book presents a comprehensive view of the development in the fields of pharmacological protection of the myocardium and the pharmacology of the vascular system. Organized into two sections encompassing 70 chapters, this volume begins with an overview of the ischemic biochemical changes with emphasis on the role of cAMP and the protein kinase system. This text then explores the cellular electrophysiological disorders seen in acute myocardial ischemia as well as their pharmacological modification. Other chapters consider the prevention of primary ventricular fibrillation that includes measures aimed at maintaining electrical stability. The final chapter deals with drugs affecting beneficially the pathological lipoprotein levels. This book is a valuable resource for cardiologists and pharmacologists.

Autoren/Hrsg.

Knoll, J.

Kelemen, K.

Inhaltsverzeichnis

1;Front Cover;1
2;Pharmacological Protection of the Myocardium;4
3;Copyright Page;5
4;Table of Contents;8
5;PREFACE;6
6;Section 1: PHARMACOLOGICAL PROTECTION OF THE MYOCARDIUM;16
6.1;INTRODUCTION;18
6.2;Chapter 1. THE CYCLIC AMP—PROTEIN KINASE SYSTEM IN ACUTE MYOCARDIAL ISCHAEMIA;20
6.2.1;CYCLIC AMP AND CYCLIC AMP-DEPENDENT PROTEIN KINASE AS INTERMEDIATES IN THE CATECHOLAMINE-PHOSPHORYLASE CASCADE;20
6.2.2;ASSAYING CYCLIC AMP-DEPENDENT PROTEIN KINASE ACTIVITY IN DOG MYOCARDIUM;21
6.2.3;EFFECT OF PROPRANOLOL;24
6.2.4;CLINICAL IMPLICATIONS;25
6.2.5;References;25
6.3;Chapter 2. CELLULAR ELECTROPHYSIOLOGICAL DISORDERS IN ACUTE MYOCARDIAL ISCHAEMIA AND THEIR MODIFICATION BY DRUGS;28
6.3.1;Basic electrical phenom^ena;28
6.3.2;Ischaemic milieu;30
6.3.3;Drug modification;33
6.3.4;Resuperfusion - an ' in vitro' model of reperfusion;35
6.3.5;References;36
6.4;Chapter 3. ANTIARRHYTHMIC EFFECTS OF POSSIBLE ANTI-ISCHEMIC DRUGS;40
6.4.1;INTRODUCTION;40
6.4.2;METHODS;41
6.4.3;RESULTS;41
6.4.4;DISCUSSION;44
6.4.5;REFERENCES;45
6.5;Chapter 4. PROTECTION OF THE ISCHAEMIC HEART. PREVENTION OF PRIMARY VENTRICULAR FIBRILLATION;48
6.5.1;Table 1. Possible mode of action of cardioprotective drugs;49
6.5.2;Table 2. Influence of Iinoleic acid rich /LAR/1 diet on changesd due to coronary occlusion in the conscious rat infarction mode;49
6.5.3;Table 3. Antiischaemic drugs;50
6.5.4;Table 4. Indicators of cardiac antiischaemic action;51
6.5.5;Table 5. Non-steroid antiinflammatory drugs given 60 mln bcforo occlusion or. survival rate, incidence of VF and size of infarctod area after coronary occlusion In the conscious rat;51
6.5.6;Table 6. Effect of chloroquine on survival rate, latency from occlusion to first arrhythmia, duration of arrhythmias of ventricular fibrillation / VF/ and ventricular tachycardia / VT/ in the conscious rat infarction model;53
6.5.7;Table 7.Cytoprotective drugs;54
6.5.8;Table 8.Indicators ot cytoprotective action;55
6.5.9;References;56
6.6;Chapter 5. REFLECTIONS ON THE MODE OF ACTION OF BETA-ADRENOCEPTOR ANTAGONISTS IN PROLONGING LIFE AFTER ACUTE MYOCARDIAL INFARCTION;60
6.6.1;TRIGGER EVENTS;62
6.6.2;EFFECTS OF BETA BLOCKADE ON FACTORS PREDISPOSING TO SUDDEN DEATH;62
6.6.3;CONCLUSIONS;64
6.6.4;REFERENCES;65
6.7;Chapter 6. CARDIOPROTECTIVE AND CEREBROPROTECTIVE EFFECT OF LIPOCORTIN-LIKE SUBSTANCES;68
6.7.1;Abstract;68
6.7.2;Introduction;68
6.7.3;Methods;69
6.7.4;Results and discussion;70
6.7.5;References;72
6.8;Chapter 7. ANTIISCHAEMIC ACTIONS OF CALCIUM ANTAGONISTS;76
6.8.1;DETERMINANTS OF CARDIAC ISCHAEMIA;76
6.8.2;ACTIVITY OF HUMAN CORONARY ARTERIES;78
6.8.3;PROTECTION OF ISCHAEMIC MYOCARDIUM;79
6.8.4;References;80
6.9;Chapter 8. CARDIO-PROTECTIVE AND -NONPROTECTIVE EFFECTS

OF DRUGS DURING ANOXIA AND REOXYGENATION;82
6.9.1;A/ Precursors of NAD- and Adenine Nucleotide /AN/-Synthesis;82
6.9.2;B/ The energy State during K+-Depolarization /13, 14/;83
6.9.3;C/ Cardiotonic Drugs and Anoxic Contractile Work/Beat 13,4,15/;84
6.9.4;D/ Reoxygenation and Auxotonic Contractile Work/Beat Influenced by Eicosanoids /16/;84
6.9.5;Acknowledgements;85
6.9.6;References;85
6.10;Chapter 9. CARDIAC GLYCOSIDES AND MYOCARDIAL ISCHAEMIA;88
6.10.1;A/ THE ACTIONS OF CARDIAC GLYCOSIDES WHICH ARE HARMFUL IN ISCHAEMIA OR INFARCTION;88
6.10.2;./ FACTORS IN ISCHAEMIA OR INFARCTION THAT INCREASE SENSITIVITYOF THE HEART TO CARDIAC GLYCOSIDES AND LOWER TOLERANCE TO TOXIC EFFECTS;90
6.10.3;C/ BENEFICIAL ACTION OF CARDIAC GLYCOSIDES IN ISCHAEMIA AND

INFARCTION;92
6.10.4;References;92
6.11;Chapter 10. PHARMACOLOGICAL CONTROL OF THROMBOTIC PROCESSES FOR PREVENTION OF MYOCARDIAL ISCHAEMIA;96
6.11.1;Introduction;96
6.11.2;PHARMACOLOGICAL CONTROL;97
6.11.3;REFERENCES;101
6.12;Chapter 11. THE PHARMACOLOGICAL PROTECTION OF THE ISCHAEMIC MYOCARDIUM PROBLEMS AND POSSIBILITIES;104
6.12.1;PROBLEMS CONCERNING THE ASSESSMENT OF THE EFFICACY OF PHARMACOLOGICAL AGENTS IN REDUCING MYOCARDIAL ISCHAEMIC DAMAGE;104
6.12.2;POSSIBLE PHARMACOLOGICAL APPROACHES TO MYOCARDIAL SALVAGE;108
6.12.3;Conclusions;111
6.12.4;References;112
6.13;Chapter 12. ETHACIZINE: ANTIARRHYTHMIC AND ANTIISCHAEMIC PROPERTIES;114
6.13.1;References;117
6.14;Chapter 13. EFFECTS OF DILTIAZEM AND VERAPAMIL IN A NEW CANINE MODEL OF MYOCARDIAL INFARCTION;118
6.14.1;Introduction;118
6.14.2;Methods;118
6.14.3;Results;119
6.14.4;Discussion;121
6.14.5;References;122
6.15;Chapter 14. POSSIBLE DIFFERENCES AMONG THE DRUG-INDUCED RESPONSES OF THE DESCENDING AND CIRCUMFLEX CORONARY ARTERIES IN THE ANAESTHETIZED DOG;124
6.15.1;Reference;127
6.16;Chapter 15. BETA-ADRENOLYTIC WITHDRAWAL REBOUND PHENOMENON: AN INTRODUCTION;128
6.16.1;References;130
6.17;Chapter 16. A CONTRIBUTION TO THE MECHANISM OF BETA-ADRENOLYTIC WITHDRAWAL SYNDROME;132
6.17.1;References;135
6.18;Chapter 17. ALTERATIONS IN THE EFFICACYOF BETA-ADRENOTROPIC DRUGS DUE TO CHANGES IN THE TONE OF THE AUTONOMIC NERVOUS SYSTEM;136
6.18.1;References;138
6.19;Chapter 18. ARTERIOVENOUS DIFFERENCE IN THE INHIBITION OF PLATELET AGGREGATION BY THE ANTIANGINAL DRUG: CH-102;140
6.19.1;Introduction;140
6.19.2;Methods;140
6.19.3;Results and discussion;141
6.19.4;References;143
6.20;Chapter 19. INHIBITION OF ADENYLATE CYCLASE BY Ca2+ IN THE ISCHAEMIC MYOCARDIUM A CONCEPT OF PROTECTION BY Ca2+ CHANNEL AND ß-BL0CKADE;144
6.20.1;EFFECT OF ISCHAEMIA AND REPERFUSION ON ISO PROTERENOL STIMULATED ADENYLATE CYCLASE;145
6.20.2;References;147
6.21;Chapter 20. PROTECTIVE EFFECT OF CALCIUM ANTAGONISTS ON ISCHAEMIC MYOCARDIAL METABOLISM DUE TO VASOPRESSIN INDUCED CORONARY SPASM;150
6.21.1;References;153
6.22;Chapter 21. INHIBITION OF cAMP-PHOSPHODIESTERASE FROM HEART AND CORONARY ARTERIES BY A NEW TRAPIDIL DERIVATIVE;154
6.22.1;References;156
6.23;Chapter 22. COMPARISON OF THREE CALCIUM ANTAGONISTS,

VERAPAMIL, DILTIAZEM AND FENDILINE ON THE ENERGETIC STATE OF ISOLATED LANGENDORFF RAT HEART;158
6.23.1;Introduction;158
6.23.2;Methods;158
6.23.3;Results;159
6.23.4;Discussion and conclusions;161
6.23.5;References;161
6.24;Chapter 23. EFFECT OF IS, A WATER SOLUBLE DERIVATIVE OF INDOMETHACIN, ON THE OUTCOME OF THE VERY EARLY PHASE OF EXPERIMENTAL MYOCARDIAL INFARCTION IN CONSCIOUS RATS;162
6.24.1;Introduction;162
6.24.2;Methods;162
6.24.3;Results;163
6.24.4;Discussion;164
6.24.5;References;165
6.25;Chapter 24. THE USE OF VOLTAGE CLAMP IN THE TESTING OF ANTIARRHYTHMIC DRUGS;166
6.25.1;References;171
6.26;Chapter 25. INTRACELLULAR ELECTROPHYSIOLOGICAL EFFECTS OF AMIODARONE AFTER ACUTE AND CHRONIC APPLICATION IN GUINEA PIG VENTRICULAR AND DOG PURKINJE FIBERS;174
6.26.1;Methods;174
6.26.2;Results;175
6.26.3;Conclusions;177
6.26.4;References;177
6.27;Chapter 26. ELECTRICAL AND MECHANICAL ACTIVITY OF THE MYOCARDIUM AS AFFECTED BY CH-101, AN ANTIARRHYTHMIC AGENT WITH PREFERENTIAL SUPRAVENTRICULAR ACTION;178
6.27.1;Introduction;178
6.27.2;Methods;178
6.27.3;Results;179
6.27.4;Conclusions;181
6.27.5;References;181
6.28;Chapter 27. INVOLVEMENT OF THE CENTRAL NICOTINIC RECEPTORS IN THE GENESIS OF THE CENTROGENIC CARDIAC ARRHYTHMIAS IN RATS;184
6.28.1;Introduction;184
6.28.2;Methods;184
6.28.3;Results;185
6.28.4;Discussion;185
6.28.5;References;187
6.29;Chapter 28. MORPHINE AND TIFLUADOM-INDUCED CENTROGENIC ARRHYTHMIAS IN ANAESTHETIZED RATS;188
6.29.1;Introduction;188
6.29.2;Methods;188
6.29.3;Results;189
6.29.4;Discussion;189
6.29.5;References;190
6.30;Chapter 29. STRUCTURE—ANTIARRHYTHMIC ACTIVITY RELATIONSHIP

OF THE AMINO-ALCOHOL DERIVATIVES;192
6.30.1;References;195
6.31;Chapter 30. LONG TERM-TREATMENT

OF CARDIAC ARRHYTHMIAS WITH NADOLOL;198
6.31.1;Material and Methods;198
6.31.2;Results;199
6.31.3;Discussion;200
6.31.4;Conclusions;200
6.31.5;References;200
6.32;Chapter 31
. ELECTROPHYSIOLOGICAL BASES OF ANTIFIBRILLATORY ACTION OF CHINOIN-103;202
6.32.1;References;205
6.33;Chapter 32.MICROELECTROPHYSIOLOGICAL PROCEDURE

FOR THE ANALYSIS OF DRUG EFFECTS ON THE ATRIOVENTRICULAR CONDUCTING SYSTEM;206
6.33.1;Introduction;206
6.33.2;Material and Methods;206
6.33.3;Results and Discussion;208
6.33.4;References;209
6.34;Chapter 33. SERUM LEVELS OF DIGOXIN DURING COMBINED TREATMENT WITH DIGOXIN AND AMIODARONE;212
6.34.1;Material and methods;212
6.34.2;Results;212
6.34.3;Discussion;213
6.34.4;Conclusion;214
6.35;Chapter 34.THE INOTROPIC EFFECT OF ISOPROTERENOL AND DOPAMINE UNDER DIFFERENT LEVELS OF OXYGENATION;216
6.35.1;Introduction;216
6.35.2;Methods;216
6.35.3;Results;216
6.35.4;Discussion;217
6.35.5;References;219
6.36;Chapter 35. THE INFLUENCE OF DOXORUBICIN COMBINED WITH OTHER DRUGS ON HAEMODYNAMIC PARAMETERS IN RABBITS;220
6.36.1;Material and methods;220
6.36.2;Results;221
6.36.3;Discussion;223
6.36.4;References;224
6.37;Chapter 36. NEW ANTIARRHYTHMIC AGENT WITH POSITIVE CARDIAC ACTIONS (GYKI-38 233);226
6.37.1;METHODS;226
6.37.2;RESULTS;227
6.37.3;CONCLUSION;230
6.37.4;REFERENCES;230
6.38;Chapter 37. CARDIAC ELECTROPHYSIOLOGICAL EFFECTS OF LYSOLECITHIN, AN ISCHAEMIC METABOLITE, ON RABBIT ATRIAL AND VENTRICULAR MYOCARDIUM;232
6.38.1;Introduction;232
6.38.2;Materials and Methods;232
6.38.3;Results and Conclusion;233
6.38.4;References;237
6.39;Chapter 38. ACUTE AND CHRONIC EFFECTSOF IPRATROPIUM BROMIDE(ITROP) IN PATIENTS WITH BRADYCARDIA;238
6.39.1;Methods;238
6.39.2;Results;239
6.39.3;Discussion;240
6.39.4;Summary;241
6.39.5;References;241
6.40;Chapter 39. MYOCARDIAL PROTECTION BY COMPUTERISED LONG-TIME CONTROLLING OF THE MYOCARDIAL GLUCOSE-, INSULIN-, FATTY ACID-SUPPLY IN MAN;242
6.40.1;References:;245
7;LIST OF CONTRIBUTORS;248
8;SUBJECT INDEX;252
9;Section 2: PHARMACOLOGY OF THE VASCULAR SYSTEM;258
9.1;Chapter 40. CHEMICAL AND BIOCHEMICAL PARAMETERS ASSOCIATED WITH NEW CARDIOVASCULAR DRUGS;260
9.1.1;REFERENCES;264
9.2;Part 1:
ROLE OF ADENOSINE RECEPTORS;266
9.2.1;Chapter 41. INTERACTIONS BETWEEN EFFECTS OF ADENOSINE AND INOSINE IN THE CORONARY CIRCULATION: A NEW HYPOTHESIS OF METABOLIC AUTO REGULATION;268
9.2.1.1;METHODS;269
9.2.1.2;RESULTS;270
9.2.1.3;DISCUSSION;274
9.2.1.4;SUMMARY;275
9.2.1.5;REFERENCES;276
9.2.2;Chapter 42. A PHARMACOLOGICAL APPROACH TO ADENOSINE RECEPTORS IN MYOCARDIUM, SINOATRIAL NODE AND VASCULAR SMOOTH MUSCLE;278
9.2.2.1;METHODS AND MATERIALS;278
9.2.2.2;RESULTS;279
9.2.2.3;DISCUSSION;282
9.2.2.4;REFERENCES;283
9.3;Part 2: CENTRAL MECHANISMS AND ACTIONS IN HYPERTENSION;286
9.3.1;Chapter 43. ADRENERGIC-OPIOID INTERACTIONS IN CENTRAL CARDIOVASCULAR AND PAIN CONTROL;288
9.3.1.1;CENTRAL SITE OF THE CLONIDINE-BETA-ENDORPHIN INTERACTION;288
9.3.1.2;ADRENERGIC-OPIOID INTERACTION IN NOCICEPTION;290
9.3.1.3;REFERENCES;291
9.3.2;Chapter 44. BETA-ENDORPHIN AND ANTIHYPERTENSIVE DRUGS;294
9.3.2.1;Prazosin-clonidine and prazosin-guanfacine interaction;295
9.3.2.2;Non adrenergic antihypertensive agents and plasma beta-endorphin;296
9.3.2.3;Conclusion;298
9.3.2.4;References;299
9.3.3;Chapter 45. THE RESPONSIVENESS OF ALPHA2-ADRENOCEPTORS IN SOME BRAIN REGIONS OF SPONTANEOUS AND VASOPRESSIN HYPERTENSIVE RATS;302
9.3.3.1;METHOD;302
9.3.3.2;RESULTS;303
9.3.3.3;Discussion;304
9.3.3.4;REFERENCES;306
9.3.4;Chapter 46. INTERFERENCE OF BLOOD PRESSURE VARIATION WITH THE EFFECT OF ANTIHYPERTENSIVE DRUGS IN NORMOTENSIVE MONKEYS MACACA MULATTA;308
9.3.4.1;Origin of animals;308
9.3.4.2;Housing;308
9.3.4.3;Blood pressure measurement;308
9.3.4.4;Blood pressure of untreated animals;309
9.3.4.5;Fluctuations of BP in untreated animals;309
9.3.4.6;Criteria for estimation of hypotensive effect;312
9.3.4.7;Effect of clinically active antihypertensive drugs;312
9.3.5;Chapter 47. THE INFLUENCE OF GABA-ERGIC SYSTEM —A NEW WAY IN PROPHYLAXIS AND TREATMENT OF HYPERTENSION IN EXPERIMENT;314
9.3.6;Chapter 48. HAEMODYNAMIC INTERACTIONS BETWEEN GUANFACINE AND ENDRALLAZINE IN HYPERTENSIVE PATIENTS;318
9.3.6.1;INTRODUCTION;318
9.3.6.2;MATERIALS AND METHODS;318
9.3.6.3;EXPERLMENTAL DESIGN;318
9.3.6.4;METHODS;318
9.3.6.5;STATISTICAL A
NIALYSIS;319
9.3.6.6;RESULTS;319
9.3.6.7;DISCUSSION;320
9.3.6.8;References;321
9.4;Part 3: ROLE OF CALCIUM ANTAGONISTS AND IN FLUENCE OF CALCIUM FLUXES;322
9.4.1;Chapter 49. ROLE OF CALCIUM ANTAGONISTS IN THE TREATMENT OF HYPERTENSION;324
9.4.1.1;Summary;324
9.4.1.2;Intracellular calcium correlates with blood pressure;325
9.4.1.3;Enhanced adrenoceptor-mediated and calcium influx dependent

vasoconstriction;326
9.4.1.4;Counterregulation codetermines antihypertensive response;327
9.4.1.5;Antihypertensive efficacy of calcium antagonists;328
9.4.1.6;References;331
9.4.2;Chaptar 50. THE EFFECT OF CALCIUM CHANNEL BLOCKERS ON THE RELEASE OF TRITIATED NORADRENALINE FROM THE PULMONARY ARTERY OF RABBIT;334
9.4.2.1;Introduction;334
9.4.2.2;Material and methods;334
9.4.2.3;Results;335
9.4.2.4;Discussion;336
9.4.2.5;References;337
9.4.3;Chapter 51. BLOOD PRESSURE LOWERING EFFECT OF NIFEDIPINE: ITS RELATIONSHIP WITH EXCHANGEABLE BODY SODIUM;338
9.4.3.1;Materials and methods;338
9.4.3.2;Results;339
9.4.3.3;Discussion;340
9.4.3.4;Conclusion;341
9.4.3.5;References;341
9.4.4;Chapter 52. ANALYSIS OF THE CALCIUM CHANNEL BLOCKERS;342
9.4.5;Chapter 53. COMPARATIVE CARDIOVASCULAR EFFECTS OF PRAZOSIN AND VERAPAMIL;344
9.4.5.1;METHODS;344
9.4.5.2;RESULTS;345
9.4.5.3;DISCUSSION;349
9.4.5.4;REFERNCES;349
9.4.6;Chapter 54. DRUG INTERACTIONS ON THE SMOOTH MUSCLES OF THE ISOLATED SPIRALLY CUT STRIP OF RAT AORTA;350
9.4.7;chapter 55. EFFECTS OF ISOQUINOLINE DERIVATIVES ON CYCLIC NUCLEOTIDES AND CALCIUM FLUXESIN RAT BLOOD VESSELS;354
9.4.7.1;REFERENCES:;357
9.5;Part 4:
ROLE OF VASODILATORS;358
9.5.1;Chapter 56. REPORT ON THE PHARMACOLOGICAL EFFECTS OF THREE NEW PERIPHERAL VASODILATOR COMPOUNDS RGH-0537, RGH-2981 AND RGH-2970;360
9.5.1.1;INTRODUCTION;360
9.5.1.2;METHODS;360
9.5.1.3;RESULTS;362
9.5.1.4;LITERATURE;363
9.5.2;Chapter 57. HEMODYNAMIC EFFECTS OF VASODILATORS ON PERIPHERAL CIRCULATION;364
9.5.3;Chapter 58. THE INFLUENCE OF AMEZINIUM ON REGULATION

OF ARTERIAL PRESSURE;368
9.5.3.1;Material and methods;368
9.5.3.2;Results;369
9.5.3.3;Discussion;370
9.5.3.4;Conclusions;370
9.5.3.5;References;370
9.5.4;Chapter 59. CIRCULATORY EFFECTS OF FUSARIC ACID DERIVATIVES;372
9.5.4.1;1./ Effects on the Normotonic Narcotised Rat;372
9.5.4.2;2./ Effects on the Spontaneously Hypertensive Rat;372
9.5.4.3;3./ Examinations on the Isolated Papillary Muscle of the Rabbit;373
9.5.4.4;4./ Examinations on the Cat;373
9.5.4.5;5./ Further effects and Summary;373
9.5.4.6;REFERENCES;373
9.5.5;Chapter60. PHARMACOLOGICAL INVESTIGATÓIONS OF THE CH-141, A NEW ISOQUINOLYL-OXADIAZINE DERIVATIVE;374
9.5.5.1;References;376
9.6;Part 5: ROLE OF ALPHA- AND BETA-ADRENERGIC AND 5-HT RECEPTORS;378
9.6.1;Chapter 61. REGULATION OF ALPHA-ADRENERGIC RECEPTORS IN DOGS'

MYOCARDIUM AND THE CORONARY ARTERY;380
9.6.1.1;INTRODUCTION;380
9.6.1.2;METHODS;380
9.6.1.3;DISCUSSION AND CONCLUSION;382
9.6.1.4;REFERENCES;383
9.6.2;Chapter 62.THE EFFECTS OF PENTACAINE AND RELATED LOCALANAESTHETICS ON BETA-ADRENERGIC RECEPTORS AND ADENYLATE CYCLASE ACTIVITY IN TURKEY ERYTHROCYTE AND RAT LIVER MEMBRANES;384
9.6.2.1;Introduction;384
9.6.2.2;Materials and methods;384
9.6.2.3;Results and Discussion;385
9.6.2.4;Summary;386
9.6.2.5;References;387
9.6.3;Chapter 63. A CONTRIBUTION TO THE MECHANISM OF BETA-ADRENOLYTIC WITHDRAWAL SYNDROME;388
9.6.3.1;REFERENCES;390
9.6.4;Chapter 64. THE EFFECT OF BETA–ADRENOCEPTOR BLOCKING DRUGS ON PLATELET AGGREGATION, CALCIUM DISPLACEMENT AND FLUIDIZATION OF THE MEMBRANE;392
9.6.4.1;ABSTRACT;392
9.6.4.2;INTRODUCTION;392
9.6.4.3;METHODS AND MATERIALS;392
9.6.4.4;RESULTS AND DISCUSSION;393
9.6.4.5;REFERENCES;395
9.6.5;Chapter 65. EFFECTS OF TOBANUM AND PROPRANOLOL

ON PLATELET AGGREGATION EX VIVO;396
9.6.5.1;Patients and methods;396
9.6.5.2;Results and discussion;397
9.6.5.3;References;397
9.6.6;Chapter 66. INTERACTION OF DIHYDROERGOTAMINE WITH 5-HT RECEPTORS ON HUMAN BLOOD PLATELETS AND FEMORAL VEINS;398
9.6.7;Chapter 67. EFFECTS OF FORSKOLIN, TREQUINSINE AND ISOPROTERENOL ON NOREPINEPHRINE-INDUCED CONTRACTIONS, cAMP AND cGMP LEVELS OF ISOLATED VASCULAR TISSUE;402
9.6.7.1;SUMMARY;402
9.6.7.2;METHODS;402
9.6.7.3;RESULTS;403
9.6.7.4;DISCUSSION;404
9.6.7.5;REFERENCES;405
9.7;Part 6:
ACTIONS ON THE PULMONARY ARTERY;406
9.7.1;Chapter 68. OUABAIN EVOKED 3[H]-NORADRENALINE RELEASE FROM THE MAIN PULMONARY ARTERY OF THE RABBIT;408
9.7.1.1;INTRODUCTION;408
9.7.1.2;METHODS;408
9.7.1.3;RESULTS AND CONCLUSIONS;409
9.7.1.4;REFERENCES;411
9.7.2;Chapter 69. PHARMACOLOGICAL ACTIONS AND THE PULMONARY CIRCULATION;414
9.7.2.1;Method;414
9.7.2.2;Results and Discussion;414
9.7.2.3;Conclusion;416
9.7.2.4;References :;417
9.8;Part 7:
INFLUENCE OF THE LIPOPROTEIN LEVEL;418
9.8.1;Chapter 70. EFFECT OF A NEW BENZHYDROLE DERIVATIVE (RGH-2801)ON THE LIPOPROTEIN AND LCAT LEVEL;420
9.8.1.1;MATERIALS AND METHODS;420
9.8.1.2;RESULTS;420
9.8.1.3;DISCUSSION;422
9.8.1.4;REFERENCES;423
9.8.1.5;ACKNOWLEDGMENTS;423
10;SUBJECT INDEX;430